A normal genetic variation modulates synaptic MMP-9 protein levels and the severity of schizophrenia symptoms

Katarzyna Lepeta, Katarzyna J Purzycka, Katarzyna Pachulska-Wieczorek, Marina Mitjans, Martin Begemann, Behnam Vafadari, Krystian Bijata, Ryszard W Adamiak, Hannelore Ehrenreich, Magdalena Dziembowska & Leszek Kaczmarek

Abstract

Matrix metalloproteinase 9 (MMP-9) has recently emerged as a molecule that contributes to pathological synaptic plasticity in schizophrenia, but explanation of the underlying mechanisms has been missing. In the present study, we performed a phenotype-based genetic association study (PGAS) in > 1,000 schizophrenia patients from the Göttingen Research Association for Schizophrenia (GRAS) data collection and found an association between the MMP-9 rs20544 A/T single-nucleotide polymorphism (SNP) located in the 3’ untranslated region (UTR) and the severity of a chronic delusional syndrome. In cultured neurons, the rs20544 SNP influenced synaptic MMP-9 activity and the morphology of dendritic spines. We demonstrated that Fragile X mental retardation protein (FMRP) bound the MMP-9 3’UTR. We also found dramatic changes in RNA structure folding and alterations in the affinity of FMRP for mRNA, depending on the SNP variant. Finally, we observed greater sensitivity to psychosis-related locomotor hyperactivity in MMP-9 heterozygous mice. We propose a novel mechanism that involves MMP-9-dependent changes in dendritic spine morphology and the pathophysiology of schizophrenia, providing the first mechanistic insights into the way in which the single base change in the MMP-9 gene (rs20544) influences gene function and results in phenotypic changes observed in schizophrenia patients.

Keywords: dendritic spine morphology; Fragile X mental retardation protein; matrix metalloproteinase 9; phenotype-based genetic association study; single-nucleotide polymorphism

Subject Categories: Chromatin, Epigenetics, Genomics & Functional Genomics; Genetics; Gene Therapy & Genetic Disease; Neuroscience

Introduction

Matrix metalloproteinase 9 (MMP-9) plays a pivotal role in synaptic plasticity that underlies physiological processes and brain pathologies (Huntley, 2012; Vafadari et al., 2016). In response to glutamate activity, locally translated MMP-9 is further released from dendritic spines that harbor excitatory synapses (Wilczynski et al., 2008; Szepesi et al., 2013). Once activated, MMP-9 cleaves specific substrates, such as adhesion molecules and cell surface receptors (Vafadari et al., 2016), inducing downstream signaling and morphological changes. The morphology of dendritic spines correlates with their functional parameters (Arellano et al., 2007), and the aberrant morphology of dendritic spines is associated with multiple brain disorders (Lin & Koleske, 2010; Penzes et al., 2011). Alterations in synaptic MMP-9 abundance have been associated with numerous brain pathologies, including epilepsy, autism spectrum disorders, and alcohol and cocaine addiction (Levy et al., 2014; Lepeta & Kaczmarek, 2015; Vafadari et al., 2016).

Schizophrenia is a complex neuropsychiatric disorder that involves impairments in perception and cognition, as well as in avolition, culminating in a triad of positive, negative, and cognitive symptoms. Paramount features of the disease are perturbations in synaptic connectivity in the prefrontal cortex, impairments in N-methyl-D-aspartate (NMDA) signaling, and dendritic spine dysfunctions (Penzes et al., 2011; Glausier & Lewis, 2013). Notably,
recent extensive genomewide association study (GWAS) identified the involvement of dendritic spines and synapse-related processes in schizophrenia but not in bipolar or major depressive disorder (Network and Pathway Analysis Subgroup of Psychiatric Genomics Consortium, 2015).

The well-established role of MMP-9 in regulating NMDA signaling, dendritic spine morphology, and prefrontal and hippocampal function (Huntley, 2012; Vafadari et al, 2016) has drawn attention to the potential involvement of MMP-9 in the development of schizophrenia (Lepeța & Kaczmarek, 2015). Domenici et al (2010) reported elevated plasma levels of MMP-9 and its endogenous inhibitor, tissue inhibitor of matrix metalloproteinases (TIMP-1), in schizophrenia patients (also see Chang et al, 2011; Yamamori et al, 2013). Moreover, two independent studies found association of MMP-9 promoter polymorphism −1562C/T (rs3918342) with schizophrenia (Rybakowski et al, 2009; Han et al, 2011). Furthermore, MMP-9 mRNA levels were strikingly upregulated in blood cells in treatment-naive schizophrenia patients to decline after antipsychotic treatment (Kumarasinghe et al, 2013). Moreover, the chromosome region 20q11-13, where the MMP-9 gene is located (Jean et al, 1995), has been linked to schizophrenia (Gurling et al, 2001).

Recent studies have shown that the synaptic translation of MMP-9 is regulated by Fragile X mental retardation protein (FMRP) (Dziembowska et al, 2012; Janusz et al, 2013; Gkogkas et al, 2014). FMRP is an RNA binding protein that is known to translationally repress the pool of neuronal mRNAs (Darnell et al, 2001; Zalía et al, 2003; Hou et al, 2006; Muddashetty et al, 2007). Missing FMRP leads to Fragile X syndrome (FXS) (Rudelli et al, 1985). FMRP has also been implicated in affective disorders, attention-deficit/hyperactivity disorder, bipolar disorder, and schizophrenia [reviewed in Bryant and Yazdani (2016)]. Interestingly, aberrations in dendritic spines that are observed in FXS patients (Rudelli et al, 1985) and Fmr1 knockout mice (Comery et al, 1997) have been linked to elevated synaptic levels of MMP-9 (Bilousova et al, 2009; Dziembowska et al, 2013; Gkogkas et al, 2014; Sidhu et al, 2014).

In the present translational study, we report an association between the MMP-9 rs20544 C/T single-nucleotide polymorphism (SNP) in the 3′untranslated region (UTR) with the severity of schizophrenia symptoms. The 3′UTR plays an essential role in mRNA transport and local translation, thus influencing protein abundance at synapses (Martin & Ephrussi, 2009). We hypothesized that the MMP-9 rs20544 SNP may affect synaptic availability of the enzyme and mediate the observed phenotype. We found that the MMP-9 C variant produces lower MMP-9 activity at the synapse than MMP-9 T, paralleled by differences in the distribution of the dendritic spine shape. To elucidate the underlying mechanism, we identified dramatic changes in RNA structure folding and alterations in the affinity of FMRP for MMP-9 RNA that depended on the polymorphic variant.

Results

**Case–control analysis does not reveal an influence of the MMP-9 rs20544 SNP on the risk of schizophrenia**

To first evaluate whether the MMP-9 rs20544 SNP is a risk SNP for schizophrenia, a case–control analysis was performed (n = 1,087 schizophrenia patients vs. n = 1,235 healthy controls; Hardy–Weinberg P > 0.05). This analysis found that rs20544 did not contribute to a higher risk of schizophrenia in our population, demonstrated by genotypic and allelic χ2 comparisons (genotypic: χ2 = 0.948, df = 2, P = 0.623; allelic: χ2 = 0.195, df = 1, P = 0.659; Fig 1A).

**Schizophrenia patients who carry the MMP-9 rs20544 CC/CT genotype display more severe chronic delusions**

To search for potential behavioral consequences of MMP-9 rs20544 variants, we conducted a phenotype-based genetic association study (PGAS) in schizophrenia patients from the Göttingen Research Association for Schizophrenia (GRAS) data collection (Begemann et al, 2010; Ribbe et al, 2010). PGAS revealed a chronic delusion syndrome as the best-suited target phenotype. The respective PANSS items taken together most adequately reflect the behavioral phenotype that is associated with the risk genotype (C allele). Therefore, a chronic delusion composite score was generated that enables quantification and is characterized by excellent internal consistency of its subitems (Cronbach’s α = 0.833; Fig 1B). Operationalization of the chronic delusion composite score is explained in Materials and Methods. The chronic delusion composite score showed a significant genotype (rs20544) association. Individuals who carried the C allele (CC/CT) had a higher score than TT carriers (P = 0.0003; Fig 1C). The PANSS P1 item “delusions” made a major contribution to the score (Fig 1D) and could have been used as single readout. However, PANSS P1 does not distinguish between acute or chronic delusion. Considering the other (borderline) significant subitems of the chronic delusion composite score yields a better description of the clinical picture of risk allele carriers, which is associated with social and emotional withdrawal, somatic concern, unusual thought content, and preoccupation (Fig 1D). Basic sociodemographic information as well as general and schizophrenia-related clinical parameters did not show any differences between CC/CT (risk allele) and TT carriers (Table 1).

**rs20544 C/T polymorphism affects MMP-9 mRNA structure**

Although T is replaced by U in mRNA, for simplification we refer to the MMP-9 rs20544-T variant as MMP-9_T throughout the manuscript, regardless of whether it refers to the RNA or DNA sequence. Accordingly, MMP-9 rs20544-C is referred to as MMP-9_C.

SNPs have the ability to significantly alter RNA secondary structures (Pachulska-Wieczorek et al, 2006). In silico ss-count analysis (i.e., the probability that a given chain of nucleotides is single-stranded) for the isolated human 3′UTR (192nt length) of MMP-9 mRNA demonstrated a high probability of structural changes in the region that hosted the SNP. Smaller changes were also observed elsewhere in the 3′UTR sequence. Overall, the tertiary structure of MMP-9 mRNA showed major structural differences that depended on the SNP under study (Fig EV1).

To experimentally validate the in silico structural models, RNA structure probing by selective 2′-hydroxyl acylation analyzed by primer extension (SHAPE) analysis revealed that 469nt at the 3′end of MMP-9 mRNA formed a structurally distinct domain, and this sequence fragment was used to further refine the models. Experimentally supported MMP-9_C and MMP-9_T RNA structures of 3′-terminal domains of MMP-9 mRNA that contained 3′UTR are shown
revealed that the human MMP-9 3'UTR harbored three G-rich sequences that are putative FMRP binding sites. To identify the FMRP binding sites within the MMP-9 mRNA sequence, we performed RNA electrophoretic mobility shift assay (REMSA) with labeled MMP-9 RNA probes that spanned two predicted G-rich sequences in either a wild-type form (wild-type probe) or a form that harbored either a mutation or deletion within one of the two G-rich sequences (mutant and delta probes, respectively; Fig 2B). Interestingly, we observed three shifted bands for the wild-type probe, suggesting the presence of three FMRP binding sites in the tested probe. One of the FMRP/MMP-9 RNA complex bands was clearly visible for the wild-type probe, and binding was hardly detectable for the probes that harbored a mutation or deletion (Fig 2C), indicating that FMRP interacts with this particular G-rich sequence.

**FMRP binds to G-rich sequence in MMP-9 3'UTR**

MMP-9 3'UTR in silico sequence analysis (Kikin et al., 2006) revealed that the human MMP-9 3'UTR harbored three G-rich sequences that are putative FMRP binding sites. To identify the FMRP binding sites within the MMP-9 mRNA sequence, we performed RNA electrophoretic mobility shift assay (REMSA) with labeled MMP-9 RNA probes that spanned two predicted G-rich sequences in either a wild-type form (wild-type probe) or a form that harbored either a mutation or deletion within one of the two G-rich sequences (mutant and delta probes, respectively; Fig 2B). Interestingly, we observed three shifted bands for the wild-type probe, suggesting the presence of three FMRP binding sites in the tested probe. One of the FMRP/MMP-9 RNA complex bands was clearly visible for the wild-type probe, and binding was hardly detectable for the probes that harbored a mutation or deletion (Fig 2C), indicating that FMRP interacts with this particular G-rich sequence.

**rs20544 C/T SNP affects the affinity of FMRP binding to MMP-9 mRNA**

Our RNA structure models revealed extensive structural changes in the MMP-9 mRNA molecule that depended on the rs20544 C/T polymorphism. Interestingly, one of the regions that was differentially folded for the two variants was the G-rich sequence, which may be implicated in the binding of FMRP (Fig 2A, blue boxes). The REMSA
confirmed that FMRP bound to MMP-9 RNA (see above). Therefore, we tested whether the ability of FMRP to bind MMP-9 mRNA is different for the two polymorphic variants of MMP-9 mRNA molecules.

To maximize proper RNA structure folding, we performed a REMSA (Fig 3A) with probes that spanned 469 nt of the 3’-terminal residues of MMP-9 mRNA (Fig 3B). As shown in Fig 2A, these sequence fragments formed a structurally distinct domain. The incubation of MMP-9 probes with increasing concentrations of purified FMRP resulted in the formation of FMRP/MMP-9 RNA complexes. The pattern of RNA/protein complex migration in gel was characteristic of multiple binding sites (Fig 3A). These results corresponded well with our previous experiments with shorter ~80 nt probes (Fig 2C), for which three distinct complexes were observed, further confirming the presence of multiple FMRP binding sites within the MMP-9 mRNA.

Interestingly, we found significant changes in complex migration that depended on the SNP variant. The complex with MMP-9_C RNA migrated faster than the complex with MMP-9_T, compared with the probe alone (Fig 3C). For FMRP concentrations >800 nM, we did not observe significant differences in migration (Fig 3C, last column), possibly because of saturation of the RNA probe that bound the protein. To assess the affinity of FMRP binding to MMP-9_C and MMP-9_T RNA probes, we performed a filter binding assay, indicating that FMRP bound more strongly to the MMP-9_C probe (Fig 3D) for the two complexes: $K_d = 154.3 \pm 120.0$ nM for MMP-9_C, $K_d = 154.3 \pm 240.0$ nM for MMP-9_T.

rs20544 C/T SNP influences MMP-9 activity at dendritic spines

Fragile X mental retardation protein controls the local translation of MMP-9 mRNA at the synapse, and the lack of FMRP in Fmr1 knockout mice leads to an increase in synaptic MMP-9 levels (Bilousova et al, 2009; Dziembowska et al, 2013; Janusz et al, 2013; Gokogkas et al, 2014). We investigated whether differences in FMRP binding affinity for rs20544 C/T polymorphic variants influence the synaptic availability of MMP-9. To measure synaptic MMP-9 activity, we used a DG-gelatin assay with primary rat hippocampal neurons. Neurons were transfected with a plasmid that coded for the MMP-9_C or MMP-9_T variant and constitutively expressed red fluorescent protein (RFP) to visualize cell morphology. As a readout of MMP-9 activity, a relative increase in fluorescence was measured for individual spines in time-lapse imaging before, 15 and 40 min after stimulation. cLTP of synaptic activity was produced by

**Table 1. Göttigen Research Association for Schizophrenia (GRAS) sample description.**

|                        | Total GRAS sample (N = 924–1,059)$^a$ | CC/CT carriers (N = 625–710)$^b$ | TT carriers (N = 299–343)$^b$ | $P$ value ($Z^2$ value)$^b$ |
|------------------------|--------------------------------------|----------------------------------|--------------------------------|-----------------------------|
| Age, years$^c$         | 39.27 [12.49] to 74.89                | 39.40 [12.62] to 74.89           | 38.99 [12.22] to 73.40        | $P = 0.754$ ($Z = −0.314$)  |
| Male, No. (%)          | 712 (67.2%)                           | 490 (68.4%)                      | 222 (64.7%)                   | $P = 0.228$ ($Z^2 = 1.451$) |
| Education, years$^c$   | 12.16 (3.12) [0 to 27]                | 12.14 (3.02) [0 to 23]           | 12.19 (3.34) [8 to 27]        | $P = 0.650$ ($Z = −0.454$)  |
| Cognitive composite score$^c$ | −0.014 (0.85) [−2.57 to 2.98]    | −0.023 (0.83) [−2.57 to 2.03]    | 0.006 (0.87) [−2.30 to 2.98]   | $P = 0.497$ ($Z = −0.679$)  |
| Handedness, No. R.LA$^c$ | 944 (89.9%), 73 (7%), 33 (3.1%)     | 634 (89.4%), 55 (7.8%), 20 (2.8%) | 310 (90.9%), 18 (5.3%), 13 (3.8%) | $P = 0.245$ ($Z^2 = 2.812$) |
| Duration of disease, years$^c$ | 12.88 [10.58] [0.01 to 58.44]     | 12.48 [10.48] [0.01 to 58.44]    | 13.71 [10.77] [0.04 to 51.96]   | $P = 0.054$ ($Z = −1.927$)  |
| Chlorpromazine equivalents$^c$ | 687.40 [704.84] [0 to 7375]  | 673.26 [649.17] [0 to 5728]      | 716.96 [809.24] [0 to 7375]    | $P = 0.854$ ($Z = −0.184$)  |
| GAF score$^c$          | 45.89 [17.18] [2 to 90]              | 45.38 [17.21] [5 to 90]          | 46.98 [17.07] [2 to 90]        | $P = 0.111$ ($Z = −1.592$)  |
| CGI score$^c$          | 5.57 [1.07] [2 to 8]                 | 5.60 [1.07] [2 to 8]             | 5.49 [1.07] [2 to 8]           | $P = 0.070$ ($Z = −1.809$)  |
| Current smokers, No. (%) | 726 (69.3%)                           | 491 (65.9%)                      | 235 (68.7%)                    | $P = 0.784$ ($Z^2 = 0.075$)  |
| No. cigarettes/day$^c$ | 16.40 (14.81) [0 to 80]              | 16.71 (15.32) [0 to 80]          | 15.78 (13.70) [0 to 80]        | $P = 0.804$ ($Z = −0.248$)  |
| Current cannabis use, No. (%) | 127 (12.5%)                           | 87 (12.7%)                      | 40 (12.0%)                     | $P = 0.761$ ($Z^2 = 0.093$)  |
| Alcoholism severity score$^c$ | 0.024 (0.65) [−1.25 to 1.92]      | 0.042 (0.66) [−0.95 to 1.92]     | −0.013 (0.64) [−1.25 to 1.91]   | $P = 0.240$ ($Z = −1.175$)  |

GAF, Global Assessment of Functioning (American Psychiatric Association, 2000); CGI, Clinical Global Impression (Guy, 1976).

$^a$Sample sizes vary due to missing data on phenotyping.

$^b$Statistics of the comparison between CC/CT carriers and TT carriers; Mann–Whitney U- or chi-square test used.

$^c$Mean (SD) [Range].

$^d$Cognitive composite score consists of reasoning (Leistungsprüfssystem-subtest-3), executive function (Trail-Making Test B), verbal learning & memory test (VLMF) (Begemann et al, 2010; Stepniak et al, 2015).

$^e$R = right-handers, L = left-handers, A = ambidexters.

$^f$Alcoholism severity score integrates numbers of alcohol-related detoxifications, highest amount of regular drinking, frequency of drinking, number of positive SCID (Structured Clinical Interview for DSM-IV Disorders) items, and chronicity (Ribbe et al, 2011).
treatment with forskolin, rolipram, and picrotoxin (Niedringhaus et al., 2012; Szepesi et al., 2013). cLTP has been shown to increase MMP-9 but not MMP-2 activity (Szepesi et al., 2013).

In the colocalization map between the red (RFP) and green (FITC-gelatin) channels, warmer colors correspond to higher gelatinolytic activity (Fig. 4A). Interestingly, we found that neurons that were transfected with MMP-9_C had lower MMP-9 activity 15 and 40 min after cLTP induction than observed for MMP-9_T variant (Fig. 4B).

rs20544 SNP influences the morphology of dendritic spines

Synaptic MMP-9 levels can regulate dendritic spine morphology (Vafadari et al., 2016). To test whether rs20544 C/T SNP-dependent differences in synaptic MMP-9 levels were followed by changes in dendritic spine morphology, we assessed the relative distribution of spine shapes (mushroom, thin, and stubby) in primary rat hippocampal neurons that overexpressed either the MMP-9_C or MMP-9_T variant (Fig. 4B).
MMP-9_T variant. Figure 4C shows a fragment of a dendrite with higher magnification of representative shapes of mushroom and thin spines.

Time-lapse imaging of living hippocampal neurons revealed significant changes in the distribution of dendritic spine shapes that depended on the MMP-9 rs20544 C/T SNP. Neurons that overexpressed the MMP-9_C variant had higher percentage of mushroom spines, both in the control conditions and after cLTP induction than neurons that overexpressed MMP-9_T (P < 0.001 for all timepoints; Fig 4D). In the control conditions, no difference was observed in the percentage of thin spines for the two SNP variants. However, after cLTP induction, the overexpression of MMP-9_T resulted in increased percentage of thin spines as compared to the control conditions (MMP-9_C: P < 0.05 for cLTP_{15 min} and P < 0.001 for cLTP_{40 min}; MMP-9_T: P < 0.001 for cLTP_{15 min} and P < 0.001 for cLTP_{40 min}), whereas the stimulation had no effect on thin spines distribution for either variant.

We also analyzed overall spine density, and no difference was found between the SNP variants. The number of protrusions per μm [mean ± SEM] for MMP-9_C was 0.96 ± 0.05 for baseline, 1.01 ± 0.04 for cLTP_{15 min}, and 1.06 ± 0.08 for cLTP_{40 min}. The density observed for MMP-9_T variant was 1.03 ± 0.09 for baseline, 1.15 ± 0.09 for cLTP_{15 min}, and 1.15 ± 0.09 for cLTP_{40 min}. The induction of cLTP resulted in slight increase in spine density for both variants (for MMP-9_C variant P < 0.05 for cLTP_{40 min}; and for MMP-9_T variant P < 0.01 for cLTP_{15 min} and cLTP_{40 min}) (A two-way repeated-measures ANOVA with post hoc analysis by Tukey’s multiple comparisons).

We then analyzed the main parameters of the mushroom and thin spine categories (i.e., length of thin spines and head area of mushroom spines). Head area has been shown to be proportional to

Figure 3. rs20544 C/T polymorphism affects FMRP binding to MMP-9 RNA molecule.
A Representative RNA electrophoretic mobility shift assay (REMSA) results. Labeled MMP-9 RNA probe was incubated in the absence (lanes 1 and 8) or presence of increasing amounts of purified FMRP (lanes 2–6 and 9–13). 20× molar excess of unlabeled probe was added as a competitor to confirm the specificity of the interaction (lanes 7 and 14).
B Scheme of MMP-9 mRNA indicating the location of the rs20544 polymorphism and part of the sequence that was used as a probe in the REMSA (A, C) and filter binding assay (D).
C Quantification of REMSA experiments. The relative mobility change of the protein–RNA complexes from the corresponding free probe band was plotted against increasing FMRP concentrations. For each FMRP concentration, the average distance of the shifted complex/free probe band was calculated from at least three independent experiments.
D Quantification of filter binding assay. The fraction of bound RNA was plotted against increasing FMRP concentrations. The data are from five independent experiments. Each column represents the mean counted from range of concentrations (indicated in Materials and Methods), with the final concentration shown on the abscissa.

Data information: Error bars indicate the SEM. *P < 0.05, **P < 0.01 (Student’s t-test).
Figure 4. MMP-9 activity at dendritic spines and analysis of dendritic spine morphology.

A Exemplary images from FITC-tagged gelatin (DQ-gelatin) assay showing colocalization map of FITC fluorescence that corresponds to gelatinolytic activity. Red fluorescent protein was used to label cell morphology, showing a short stretch of dendrite that overexpressed either the MMP-9_C or MMP-9_T variant. Warmer colors correspond to higher gelatinolytic activity. Dendritic spines with an increase in gelatinolytic activity are marked with arrows.

B Quantification of analyzed data from four separate experiments. The relative increase in fluorescence was measured for individual spines over time as a readout of MMP-9 activity. A total of 17 cells (MMP-9_C) or 13 cells (MMP-9_T) were analyzed.

C Image from morphological analysis of spines from primary rat hippocampal neurons showing example of mushroom and thin spine shapes.

D The rs20544 polymorphism influenced the percent distribution of spine shape. Quantification of percent distribution of mushroom and thin spines from time-lapse imaging from three separate experiments. Neurons that overexpressed MMP-9_C had more mushroom spines and less thin spines than the MMP-9_T variant. For each polymorphic variant, six cells were analyzed; the total number of spines analyzed was $n_{\text{spines}} = 419$ for MMP-9_C and $n_{\text{spines}} = 465$ for MMP-9_T.

Data information: Error bars indicate the SEM. *$P < 0.05$, **$P < 0.01$, ***$P < 0.001$ (Mann–Whitney U-test in B; two-way ANOVA with multiple comparisons in D).
MMP-9 variant.
spines, which had a larger head area compared with the MMP-9_T

tion, neurons that overexpressed MMP-9_C had more mushroom
induction both variants had similarly long thin spines. In conclu-
observed for MMP-9_T upon stimulation; therefore, after cLTP
induction caused more pronounced thin spines lengthening than
longer observed. For MMP-9_C-overexpressing neurons, cLTP
(2.05

MMP-9_T transfection (Harris & Stevens, 1989). Neurons that were transfected with
the size of the postsynaptic density and number of presynaptic vesi-
cles (Harris & Stevens, 1989). Neurons that were transfected with
MMP-9_C had a significantly larger head area as compared with
MMP-9_T transfection (P < 0.001 for all timepoints; Fig 4D). We
observed increase in head area of mushroom spines for MMP-9_T
variant upon cLTP induction (P < 0.001 for both cLTP15 min and
cLTP40 min), whereas the stimulation did not affect the head size
parameter in neurons transfected with MMP-9_C. Before stimula-
tion, neurons that overexpressed MMP-9_T had longer thin spines
(2.05 ± 0.07 μm) compared with MMP-9_C (2.53 ± 0.13 μm; P < 0.05). However, after cLTP induction, the difference was no
longer observed. For MMP-9_C-overexpressing neurons, cLTP
induction caused more pronounced thin spines lengthening than
observed for MMP-9_T upon stimulation; therefore, after cLTP
induction both variants had similarly long thin spines. In conclu-
sion, neurons that overexpressed MMP-9_C had more mushroom
spines, which had a larger head area compared with the MMP-9_T
variant.

Mmp-9 heterozygous mice exhibit increased sensitivity to
MK-801-induced locomotor hyperactivity

Our data for the MMP-9 rs20544 C/T SNP showed that C carriers
(CC/CT) exhibited more severe positive symptoms of schizophrenia
than TT carriers. The neuronal culture experiments indicated that
the Mmp-9_C variant resulted in lower MMP-9 activity after cLTP
induction compared with the MMP-9_T variant (Fig 4B). To test
whether MMP-9 levels influence performance in a behavioral model
of the positive symptoms of schizophrenia, we used Mmp-9
heterozygous mice with twofold lower levels of MMP-9 in the brain
(Fig EV2) and exposed them to psychosis-related locomotor hyper-
activity induced by NMDA receptor antagonist MK-801 (van den
Buuse, 2010). Ten minutes after MK-801 administration, Mmp-9
heterozygous mice exhibited a significant increase in the distance
traveled compared with wild-type mice (F(1,13) = 5.6163; P < 0.05; two-way repeated-measures ANOVA; Fig 5). The saline
injection did not cause hyperlocomotion. After the saline treatment,
the distance traveled by wild-type and heterozygous animals did not
differ significantly. On the other hand, the mice traveled greater
distance after MK-801 injection than after the saline injection
(F(9,117) = 46.5515; P < 0.01) and also the treatment effect vs.
genotype effect interaction was significantly different
(F(9,117) = 6.1108; P < 0.01). Therefore, lower levels of MMP-9 in
the brain in Mmp-9 heterozygous mice resulted in an increase in
MK-801-induced locomotor hyperactivity.

Discussion

In the present study, we identify a novel function of rs20544 C/T
SNP that is located in the 3’UTR of MMP-9, and we show that it is
strongly associated with the severity of a chronic delusional
syndrome in schizophrenia patients. Our case–control results
demonstrate that MMP-9 rs20544 per se is not a risk SNP for a
schizophrenia endpoint diagnosis, but schizophrenia individuals
who carry the C allele (CC/CT) are more severely affected by
chronic delusions compared with TT carriers. This analysis was
only possible based on a deeply phenotyped sample of schizo-
phrenic individuals, an inevitable prerequisite for approaching
the definition of biological disease subgroups. In fact, our results
suggest that MMP-9 contributes to an important biological subgroup
under the heterogeneous “umbrella diagnosis” of schizophrenia.
These results may also explain why the large GWAS on endpoint
diagnoses failed to extract Mmp-9 as a common risk gene for
schizophrenia (Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014).

Most importantly, we provided mechanistic insights into the way in which the single base change in MMP-9 rs20544 (C vs. T) remarkably influences gene function. Molecular analyses and structural studies showed that the rs20544 C/T SNP markedly affects the mRNA structure of MMP-9, thus influencing folding of the predicted FMRP binding site (i.e., the G-rich sequence in the 3’UTR). The MMP-9_C variant was bound by FMRP with higher affinity than the MMP-9_T variant. Previous studies showed that MMP-9 mRNA was a subject to activity-driven local translation near excitatory synapses, and FMRP is a potent inhibitor of such translation (Dziembowska et al, 2012; Janusz et al, 2013; Gkogkas et al, 2014). Interestingly, neurons that overexpressed the MMP-9_C variant exhibited lower synaptic MMP-9 activity after cLTP induction compared with neurons that overexpressed the MMP-9_T variant. Moreover, analyses of the morphology of dendritic spines that harbor excitatory synapses confirmed that cLTP-stimulated neurons overexpressing the MMP-9_T variant were more susceptible to structural plasticity induced by synaptic stimulation, as they had greater abundance of thin spines, which have been previously shown to be more plastic and immature than mushroom spines (Yuste & Bonhoeffer, 2004). A schematic diagram that depicts our proposed model is shown in Fig 6. Consistent with our observations from man to cell is our finding in MMP-9 heterozygous mice. These animals exhibited a decrease in MMP-9 levels in the brain and were more sensitive to MK-801-induced locomotor hyperactivity, a model of the positive symptoms of schizophrenia.

RNA structure probing in solution, supported by in silico modeling, revealed that the structures of the two variants of MMP-9 mRNA were strikingly different. Such marked changes in the mRNA structure can influence interactions with RNA binding proteins, such as FMRP and short non-coding microRNA molecules. Our previous studies identified FMRP as a potent regulator of the local translation of MMP-9 mRNA (Dziembowska et al, 2012; Janusz et al, 2013; Gkogkas et al, 2014).

Figure 6. Schematic model illustrating the conclusions. See text for explanation.
et al., 2013). The variant-specific structural change in the MMP-9 mRNA molecule was also seen in the region that was predicted to bind FMRP. Although FMRP was previously shown to regulate MMP-9 mRNA (Dziembowska et al., 2012; Janusz et al., 2013; Gkogkas et al., 2014), the exact sequence of the protein–RNA interaction site was not identified. Using a gel-shift assay, we found that FMRP bound MMP-9 mRNA at more than one site. Namely, the ~80 nt human wild-type REMSA probe displayed three protein complex bands (Fig 2C). Two of these binding sites likely correspond to the G-rich sequences that were identified in silico.

To assess the binding of FMRP to specific MMP-9 mRNA variants, we used ~470-nt-long probes to ensure the most optimal RNA folding. The observed differences in Kd values were relatively small, possibly reflecting the presence of multiple, yet unidentified binding sites. Additionally, the different secondary and 3D structure organization of the two MMP-9 variants suggests that although both RNA can be bound by FMRP, the complexes that are formed might not be equally functional. Indeed, the REMSA revealed different migration of the FMRP complexes with the MMP-9_T and MMP-9_C probes. Nevertheless, we observed a decrease in FMRP:MMP-9 mRNA complex formation in the presence of 50 mM lithium ions (Fig EV3), suggesting that one of the G-rich sequences that was identified as an FMRP binding site might form a G-quadruplex structure that is destabilized in the presence of lithium ions (Bardin & Leroy, 2008). It has been shown that potassium ions stabilize the G-quartet structures, whereas lithium ions greatly destabilize it (Bardin & Leroy, 2008; Lee et al., 2008).

The binding of FMRP to mRNA leads to ribosomal stalling and the inhibition of translation (Darnell et al., 2011). Therefore, we expected that its differential affinity for the MMP-9 mRNA variants may result in different synaptic MMP-9 levels. We closely studied the effects of overexpression of either MMP-9_C or MMP-9_T on neuronal activity-induced MMP-9 at dendritic spines and spine morphology. After the induction of cLTP, neurons that overexpressed the MMP-9_T variant, which is bound by FMRP with lower affinity, produced more MMP-9 at the synapse. This can be explained by the inhibitory effect of FMRP on synaptic MMP-9 translation that seems to be more pronounced in the case of the MMP-9_C variant. The higher levels of secreted MMP-9 in MMP-9_T-overexpressing neurons were accompanied by a greater prevalence of thin spines. In contrast, the MMP-9_C variant had more mushroom spines, which are considered more mature and efficient spines. For MMP-9_T transfected neurons, we observed increase in head area of mushroom spines after cLTP induction, whereas stimulation had no effect on this parameter in MMP-9_C-expressing neurons, which had bigger head size than observed for MMP-9_T variant regardless of the cLTP induction. These data are consistent with previous studies (Wang et al., 2008; Wilczynski et al., 2008; Szepesi et al., 2013, 2014; Vafadari et al., 2016), arguing that higher MMP-9 levels could confer higher spine plasticity in the MMP-9_T variant, similar to the greater abundance of thin spines and higher MMP-9 activity that are observed in FXS patients and Fmr1 knockout mice (Rudelli et al., 1985; Comery et al., 1997; Dziembowska et al., 2013). Recently, two studies reported decreased levels of FMRP in brains and blood of subjects with schizophrenia (Fatemi et al., 2010; Kovács et al., 2013). Our data suggest that different levels of FMRP do not interfere with changes in the affinity observed for the two MMP-9 mRNA variants (Fig 3D). Therefore, we assume that the alterations in the affinity of FMRP for MMP-9 RNA depending on the SNP, which we show in the present paper, would occur also in a situation of reduced levels of FMRP. Since FMRP negatively regulates MMP-9 mRNA translation and the variant resulting in lower MMP-9 activity at the spines (CC/CT) is the “risk” variant, one could speculate that the downregulation of FMRP in schizophrenia is even a compensatory mechanism to overcome decreased MMP-9 levels.

Locomotor hyperactivity that is produced by NMDA receptor antagonism is frequently used to behavioral model the positive symptoms of schizophrenia in mice (van den Buuse, 2010), in line with the “hypoglutamatergic hypothesis” of schizophrenia (Gunduz-Bruce, 2009; Radyushkin et al., 2010). Despite the obvious shortcomings in addressing uniquely human perceptions, such as hallucinations and delusions, this animal model has advanced the validation of proposed gene mechanisms in schizophrenia. Mmp-9 heterozygous mice are not the perfect model of the Mmp-9_rs20544 SNP; however, they serve in our study only as supplementary support for the main findings on molecular, morphological, and clinical consequences of the SNP. Locomotor hyperactivity in Mmp-9 heterozygous mice, which have lower levels of Mmp-9 expression in the brain, together with decreased MMP-9 activity for the “risk” MMP-9_C variant supports the previously postulated connections between MMP-9 activity, glutamate signaling, and schizophrenia (Lepeta & Kaczmarek, 2015).

In summary, our results link Mmp-9 gene polymorphisms with a specific subphenotype of schizophrenia, suggesting that the underlying mechanism depends on the local synthesis of MMP-9 within the vicinity of excitatory synapses. Synaptic MMP-9, in turn, contributes to the morphology of dendritic spines, which may be viewed as a proxy for synaptic efficacy. Interestingly, another Mmp-9 SNP −1562C/T (rs3918242) has also been shown to affect PANS score in schizophrenia patients (Ali et al., 2017). The present data are also in a good agreement with the results from a recent study that showed that gene risk variants for schizophrenia converge in biological pathways that are involved in excitatory synapses/dendritic spines (Network and Pathway Analysis Subgroup of Psychiatric Genomics Consortium TN and PAS of the PG, 2015). Neuroinflammatory events are another main trait that contributes to the pathophysiology of schizophrenia. Matrix metalloproteinases, owing to their well-known role in inflammatory responses, have been suggested as a novel drug target for the treatment of schizophrenia (Chopra et al., 2015). We propose an alternative function for MMP-9 in the pathophysiological underpinnings of schizophrenia, by pointing to a novel mechanism that involves changes in MMP-9 levels at the excitatory synapse and MMP-9-dependent changes in dendritic spine morphology. In conclusion, we found a specific association between a molecular mechanism that involves synaptic MMP-9 and a biological subgroup of schizophrenia, which may open new avenues for individualized treatment of this devastating disease in the future.

Materials and Methods

Subjects

Schizophrenia patients

Göttingen Research Association for Schizophrenia (GRAS) data collection has been ongoing for the past 10 years and consists of
> 1,100 deeply phenotyped patients who were diagnosed with schizophrenia or schizoaffective disorder according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision (American Psychiatric Association, 2000). Patients were recruited from 23 collaborating centers across Germany (Begemann et al, 2010; Ribbe et al, 2010). The study complies with the Helsinki Declaration and was approved by the Ethics Committee of the Georg-August-University (Göttingen, Germany) and all participating centers. All of the study participants (95.6% European Caucasian, 1.7% other, 2.7% unknown) or, if applicable, their legal representatives provided written informed consent to be included in the study. Of the 1,087 successfully genotyped patients, 66.7% were male ($n = 725$) and 33.3% were female ($n = 362$). Their average age was 39.44 ± 12.56 years (range, 17–79 years).

Healthy controls

For case-control analyses (Fig 1A), healthy voluntary blood donors were employed. They were recruited in the Department of Transfusion Medicine at the Georg-August-University of Göttingen according to national guidelines for blood donation. As such, they met the necessary health requirements, ensured by a broad pre-donation screening process that included standardized health questionnaires, interviews, and assessments of hemoglobin concentration, blood pressure, pulse, and body temperature. Of the 1,235 successfully genotyped control subjects (97.8% European Caucasian, 2% other, 0.2% unknown), 61.8% were male ($n = 763$) and 38.2% were female ($n = 472$). Their average age was 37.42 ± 13.22 years (range, 18–69 years).

Genotyping

The GRAS sample was genotyped using a semi-custom Axiom MyDesign Genotyping Array (Affymetrix, Santa Clara, CA, USA), based on a CEU (Caucasian residents of European ancestry from Utah, USA) marker backbone that included 518,722 SNPs and a custom marker set that included 102,537 SNPs. Genotyping was performed by Affymetrix on a GeneTitan platform. Several quality control steps were applied (SNP call rate > 97%, Fisher’s linear discriminant > 3.6, heterozygous cluster strength offset > 0.1, and homozygote ratio offset > −0.9) (Hammer et al, 2014; Stepniak et al, 2015). The genotyping results of the GRAS sample have been included in and published as part of the latest PGC study on schizophrenia (Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014).

Phenotyping and target phenotype

Göttingen Research Association for Schizophrenia schizophrenia patients were deeply phenotyped including sociodemographic, psychopathological and other disease-related readouts (Ribbe et al, 2010). Basic sociodemographic information, general and schizophrenia-related clinical readouts are presented in Table 1. Screening for a potential association between the MMP-9 rs20544 SNP and lead symptoms of schizophrenia using the Positive and Negative Syndrome Scale (PANSS) (Kay & Fiszbein, 1987) in a phenotype-based genetic association study (PGAS) approach (Hammer et al, 2014; Stepniak et al, 2014, 2015) pointed to a chronic delusional syndrome as the relevant phenotype measure. To quantify this target phenotype, a chronic delusion composite score was created, based on one item (P1) of the positive subscale of the PANSS, two items (N2 and N4) of the negative subscale, and four items (G1, G9, G15, and G16) of the general subscale (Fig 1B). Phenotypic data to construct the chronic delusion composite score were available for 1,047 patients.

Construction of DNA vectors

For the transfection of neurons, the human MMP-9 gene coding sequence with the 3′UTR was cloned under the synapsin 1 promoter into the pCRBlunt-TOPO vector (Thermo Scientific), referred to as pCR Syn MMP-9_C. The pCR Syn MMP-9_T construct was obtained by site-directed mutagenesis of the nucleotide that hosted the rs20544 C/T SNP, confirmed by sequencing. For MMP-9_C and MMP-9_T probe preparation for the RNA electrophoretic mobility shift assay, the sequence 469 nucleotides (nt) from the 3′terminus of human MMP-9 mRNA was cloned by polymerase chain reaction (PCR) into KpnI and NotI restriction sites of the pDrive vector, thus creating pDrive REMSA_C and pDrive REMSA_T plasmids. The choice of probe sequence was based on our RNA structure data to maximize the proper RNA structure folding.

In silico MMP-9 mRNA structures

RNA secondary structures were predicted using RNAstructure 5.6 (Deigan et al, 2009). The ss-count analysis was performed for the isolated 3′UTRs (192 nt) and full-length (2,336 nt) human MMP-9 RNAs. All of the secondary structures that were predicted within 10% of free energy of the most stable variant were considered, and the window size parameter was changed to generate closely related structures. For the secondary structure prediction that was supported by the experimental data, the normalized reactivity values were introduced to RNAstructure 5.6 software as pseudo-energy constraints with default slope and intercept values. The maximum pairing distance was limited to 600 for the final structures. Differences in nucleotides between groups were analyzed by applying the Wilcoxon rank sum test. The three-dimensional (3D) structures of 469 nt of the 3′-terminal fragment of MMP-9_C and MMP-9_T RNAs were generated using the RNAComposer server (http://rnacomposer.cs.put.poznan.pl; Popenda et al, 2012; Biesiada et al, 2016). Experimentally supported secondary structures were introduced as an input. The final energy values were used to rank the predicted structures.

RNA structure probing in solution

Templates for in vitro transcription were obtained by the PCR amplification of MMP-9 variants from corresponding plasmids (pCR Syn MMP-9_C and pCR Syn MMP-9_T) using a forward primer that contained a T7 promoter sequence. RNA was transcribed in vitro using MEGAscript (Life Technologies) according to the manufacturer’s protocol. RNA was treated with DNase I and recovered by LiCl precipitation. For RNA modification, 5 pmol of full-length MMP-9 RNA (MMP-9_C or MMP-9_T variant) was refolded in 100 µl of buffer that contained 10 mM Tris–HCl (pH 8.0), 100 mM KCl, and 0.1 mM ethylenediaminetetraacetic acid (EDTA) with
heating at 95°C for 2 min and then placed on ice. Afterward, 50 μl of 3° folding buffer (120 mM Tris–HCl [pH 8.0], 600 mM KCl, 1.5 mM EDTA, and 15 mM MgCl2) was added and incubated at 37°C for 20 min. In the experiments that were designed to probe the presence of quadruplex structures, the folding buffer contained 120 mM Tris–HCl (pH 8.0), 1.5 mM EDTA, 15 mM MgCl2, and 450 mM LiCl or KCl. Folded RNA was equally divided into two tubes and treated with either 8 μl of 5 mM 1-methyl-7-nitroisatoic anhydride (1m7; reaction) or DMSO alone (control) and allowed to react for 5 min at 37°C. RNA was recovered using the Direct-zol RNA MiniPrep Kit (Zymo Research).

The detection of 2°-O-adducts was performed using reverse transcription with fluorescently labeled primers as described previously (Purzycka et al., 2013; Nishida et al., 2015). Briefly, primers were added to 0.5 pmol of RNA (Cy5 [+]) and Cy5.5 [−]; 8 and 6 μM, respectively), and primer-template solutions were incubated at 95°C for 3 min, 37°C for 10 min, and 55°C for 2 min. RNA was then reverse-transcribed at 50°C for 45 min (Invitrogen Superscript III, Life Technologies). Sequencing ladders were prepared using primers that were labeled with WellRed D2 and LicorIR-800 and a Thermoscientific 3°-methylisatoic anhydride (NMIA) reactivity was normalized using the ShapeNorm script (Huang et al., 2013). Reactivity values were obtained from at least three repetitions and implemented as pseudo-energy constraints to predict RNA secondary structures. In the experiments that sought to detect quadruplexes, the primer extension reactions were performed with [32P]-labeled primers as described previously (Purzycka et al., 2011).

Preparation and biotinylation of oligonucleotides

Three types of oligonucleotides were used for the specific experiments:

1 Human wild-type, mutant, and delta MMP-9 RNA probes (~80 nt, sequences listed below) were prepared for REMSA on the template of annealed shorter overlapping oligonucleotides (~50 nt). The annealed product was subjected to PCR-based filling with Taq polymerase (Thermo Scientific) and agarose gel-purified using the Syngen Gel/PCR Mini Kit. The forward primer contained the T7 RNA polymerase promoter. The probe was purified and biotinylated as described above. This probe was used to choose the optimal FMRP concentration range for further experiments with human probes. The titration of increasing amounts of FMRP caused the appearance of a shifted band that indicated complex formation (Fig EV4). The specificity of the interaction was confirmed by competition with an excess of unlabeled probe.

Wild-type rat: 5′-TTGGTGACTTCTTCTAGAGCTAGGAAGGA GTGGAAGCGCCGGAGGCCCCCTCTCTCGCA-3′

Delta human: 5′-GTTCCTGGAGAAAGAGTTGGGTTGGG CTCCTCTTCTCACCTTTGTTTTTGTGTTGGTCTCTAAAT-3′

Human MMP-9_C and MMP-9_T probes (~470 nt) for REMSA were obtained by the digestion of pDrive REMSA_C and pDrive REMSA_T with NotI and in vitro transcription with RNA polymerase T7 (Roche). Purification and labeling were performed as described above. Biotinylation was conducted overnight.

The rat REMSA wild-type probe was prepared by ligating the annealed complementary oligonucleotide that spanned an approximately 50 nt fragment of the rat MMP-9 3°UTR (sequence listed below), including one of the G-rich sequences, into the pcRII vector (TA Cloning Kit, Thermo Scientific). The obtained plasmid was digested with EcoRV enzyme and subjected to in vitro transcription with RNA polymerase Sp6 (Roche). In addition to the MMP-9 3°UTR fragment, the probe also contained an approximately 75 nt sequence that was present in the vector between the cloning site and Sp6 promoter. The probe was purified and biotinylated as described above. This probe was used to choose the optimal FMRP concentration range for further experiments with human probes. The titration of increasing amounts of FMRP caused the appearance of a shifted band that indicated complex formation (Fig EV4). The specificity of the interaction was confirmed by competition with an excess of unlabeled probe.

Wild-type rat: 5′-TTGGTGACTTCTTCTAGAGCTAGGAAGGA GTGGAAGCGCCGGAGGCCCCCTCTCTCGCA-3′

2 Human MMP-9_C and MMP-9_T probes (~470 nt) for REMSA were obtained by the digestion of pDrive REMSA_C and pDrive REMSA_T with NotI and in vitro transcription with RNA polymerase T7 (Roche). Purification and labeling were performed as described above. Biotinylation was conducted overnight.

The rat Fmr1 nucleotide sequence was cloned into the pET28 vector using a sequence- and ligation-independent cloning (SLIC) method. The plasmid contained an N-terminal His6-tagged SUMO protein sequence that can be enzymatically cleaved by SUMO protease. The plasmid was propagated in E. coli BL21-CodonPlus-RIL and purified by the AKTA™xpress chromatography system at 10°C. Briefly, after centrifugation, the supernatant was loaded on a Ni-NTA Superflow Agarose column (Qiagen). Bound protein was on-column cleaved by SUMO protease (20 μg protease per 5 ml of resin) in elution buffer (20 mM Tris [pH 8], 600 mM NaCl, and 300 mMimidazole) for 8 h at 10°C. The cleaved protein was further purified by combinations of a HiTrap desalting column (GE Healthcare) and Ni-NTA Agarose column. Protein that was not bound with resin was collected and automatically loaded onto a Superdex 200 column (GE Healthcare) that was pre-equilibrated with GF buffer (10 mM Tris [pH 8] and 600 mM NaCl). After lowering the salt concentration to 100 mM NaCl by adding four volumes of 10 mM Tris (pH 8), the proteins were further purified by ion exchange chromatography on a ResourceQ column (GE Healthcare) that was equilibrated with LS buffer (10 mM Tris [pH 8] and 100 mM NaCl) and eluted with HS buffer (10 mM Tris [pH 8] and 1 M NaCl). Purified proteins were analyzed by 12% sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE).

FMRP purification

RNA electrophoretic mobility shift assay

RNA electrophoretic mobility shift assay was performed according to the Pierce kit’s instructions (LightShift Chemiluminescent RNA
the addition of 4 (amounts indicated in legends of Figs 2C and 3A, and EV4). After as a competitor to confirm the specificity of the interaction mixture was loaded on 5% native polyacrylamide gel (duracryl, ultraviolet-cross-linked at 120 mJ/cm² and developed according to experiments, a 20 HEPS [pH 7.6], 5% glycerol, and 50 ng/µl tRNA. In some of the experiments, a 20–200× molar excess of unlabeled probe was added as a competitor to confirm the specificity of the interaction (amounts indicated in legends of Figs 2C and 3A, and EV4). After the addition of 4 µl of 6× DNA Loading Dye (Thermo Scientific), the mixture was loaded on 5% native polyacrylamide gel (duracryl, 0.5% glycerol, and 0.5× TBE).

Electrophoresis was performed in 0.5× TBE buffer (pH ~8.3) for 2–3 h at 170 V and 4°C. After transfer, the nylon membrane was ultraviolet-cross-linked at 120 ml/cm² and developed according to the Pierce kit’s instructions (LightShift Chemiluminescent RNA EMSA Kit, Thermo Scientific). For the MMP-9_C and MMP-9_T probes, the relative mobility change of the protein–RNA complexes was calculated as the distance from the corresponding free probe band. For quantification, the relative mobility change was plotted against increasing FMRP concentrations. For each FMRP concentration, the average distance of the shifted complex/free probe band was calculated from at least three independent experiments (110–220 nM FMRP, from three independent experiments; 430 nM FMRP, from nine independent experiments; 860 nM FMRP, from eight independent experiments).

Filter binding assay

The experiments were performed as described (Nishida et al., 2015), with modifications. RNA was labeled at the 3′ end using T4 RNA ligase (Thermo Scientific) and [32P]pCp overnight at 4°C and column-purified with the Direct-zol RNA MiniPrep Kit (Zymo Research). Radiolabeled RNA probes (20 fmoles) were denatured for 2 min at 95°C and folded at 37°C for 10 min in binding buffer (10 mM Tris [pH 7.5], 50 mM KCl, and 1 mM DTT; Thermo Scientific). Renatured RNA was incubated with increasing amounts of full-length FMRP in a final volume of 20 µl for 20–30 min at room temperature and then filtered through wet nitrocellulose membranes (Protran BA79 and Amersham Hybond-N⁺) under gentle suction. After filtration, the membranes were washed twice with 200 µl of wash buffer (10 mM Tris [pH 7.5] and 50 mM KCl), dried, and exposed to a phosphorimager screen. The data were analyzed using ImageJ and GraphPad Prism 6 software. The filter binding experiments were repeated five times (MMP-9_C and MMP-9_T probes) or three times (wild-type, mutant, and delta probes).

Neuronal culture and transfection

Dissociated hippocampal cultures were prepared from postnatal day 0 (P0) wild-type Wistar rats (pups of either sex) as described previously (Jasinska et al., 2015). The neuronal cultures were co-transfected after 10 days of culture in vitro (DIV10) with vectors for the overexpression of RFP together with MMP-9_C or MMP-9_T for verification of transfection efficacy using Lipofectamine 2000 (Life Technologies), according to manufacturer’s protocol. In the pilot experiment, zymography was performed to verify overexpression of MMP-9 in culture transfected with MMP-9-C or MMP-9-T vectors comparing the levels of MMP-9 to control culture transfected only with RFP coding vector.

Cell culture stimulation and gelatinase assay in living neuronal culture

The experiments that are described below were performed on DIV19-23. The cells were first incubated in maintenance medium with a mixture of 1 µM tetrodotoxin (TTX), 40 µM 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), 100 µM (2R)-amino-5-phosphonovaleric acid (APV), and 5 µM nimodipine (all from Sigma-Aldrich) for 3 h to silence spontaneous neuronal activity. To visualize gelatinase activity, fluorescein conjugate gelatin (DQ-gelatin; Molecular Probes, catalog no. D12054) was added to the cells 30 min before the end of silencing at a final concentration of 40 ng/µl as described previously (Szepesi et al., 2014). The fluorescence of DQ-gelatin is quenched until it is digested by gelatinases, MMP-9, and MMP-2 in neuronal cultures. Therefore, an increase in fluorescence is proportional to the proteolytic activity of gelatinases. At the end of silencing, the cells were briefly washed and kept in conditioned culture medium that contained 1 µM TTX, 40 µM CNQX, 5 µM nimodipine, and a mixture of 50 µM forskolin, 0.1 µM rolipram, and 50 µM picrotoxin (all from Sigma-Aldrich), which were previously shown to induce chemical long-term potentiation (cLTP) in vitro (Otmakhov et al., 2004; Szepesi et al., 2013).

Live cell imaging

Live cell imaging was performed with 3-week-old cultured hippocampal neurons in a living chamber at 37°C in a 5% CO₂ atmosphere as described previously (Szepesi et al., 2013; Szepesi et al., 2014). As a readout of MMP-9 activity, the level of fluorescence from digested DQ-gelatin was measured for individual spines using time-lapse imaging 0, 15, and 40 min after cLTP induction. Dendritic spines from randomly selected segments of secondary or tertiary dendrites were imaged in four independent experiments (n = 17 cells for MMP-9_C and n = 13 cells for MMP-9_T; an average of 188 spines/cell for MMP-9_C and 147 spines/cell for MMP-9_C). Only dendritic spines that persisted during the entire imaging session were analyzed (nspines_C = 3,197 for MMP-9_C and nspines_T = 1,906 for MMP-9_T). Of these spines, only those that exhibited an increase in fluorescence over time were used for further quantification (nspines_cLTP 15 min = 1,134 and nspines_cLTP 40 min = 1,216 for MMP-9_C, constituting 35.47% and 38.04% of total spines, respectively; nspines_cLTP 15 min = 761 and nspines_cLTP 40 min = 736 for MMP-9_T, constituting 39.93% and 38.61% of total spines, respectively). Images were acquired using a Zeiss LSM780 confocal microscope with a 40× water-immersion objective and 488 and 561 nm laser lines at 1,024 × 1,024 pixel resolution. A series of 10 z-stacks was acquired for each cell at 0.42 µm steps, with additional digital zoom at final lateral resolution of 0.07 µm per pixel.

Images were further processed using ImageJ software (National Institutes of Health). The RFP signal (red channel) was used to create a mask that was applied to DQ-gelatin images (green channel) to enable the quantification of only transfected neurons that
overexpressed either the MMP-9_C or MMP-9_T variant. The signal was enhanced for all images by multiplication values of 1.2 for the red channel and 3 for the green channel. The x–y cell drift over time was corrected using the StackReg ImageJ plugin (Thevenaz et al., 1998). Because DQ-gelatin was washed off with changes in the medium for wash and stimulation, only gelatin that adhered to the cells remained. As a result, the overall green channel signal decreased and was corrected accordingly.

Dendritic spine analysis

For the analysis of dendritic spine morphology, images from the DQ-gelatin assay that was performed on primary rat hippocampal neurons were used (see above). Using semi-automated custom-made SpineMagick! Software (Ruszczycyki et al., 2012), the spine area, length, and width were measured. The spines were then clustered using custom scripts that were written in Python with the NumPy, SciPy, and Matplotlib into three main categories as described previously (Jasinska et al., 2015): spines with a clear head and neck (mushroom spine), filopodia-like spines (thin spines), and spines without heads (stubby spines). Clustering was further manually corrected based on average images of the clusters and visual inspection of spines that comprised the clusters. The percentage of distribution of the spine shapes was calculated for neurons that overexpressed either the MMP-9_C or MMP-9_T variant. The overall spine density was measured as a number of protrusions per μm and reported as mean ± SEM. For each polymorphic variant, six cells from three separate experiments were analyzed. The total number of spines analyzed was nspines = 419 for MMP-9_C and nspines = 465 for MMP-9_T.

Gel zymography

The cortex and hippocampi were dissected from heterozygous MMP-9+/− mice and control wild-type (MMP-9+/+) mice. Tissue was homogenized and divided into Triton-soluble and Triton-insoluble (enriched in MMP-9) fractions as described previously (Szklarczyk et al., 2002). The protein concentration in the Triton-insoluble fraction was measured using the BCA kit (Pierce). A total of 50 μg protein was loaded per lane. The samples were mixed with 5× Laemmli sample buffer and loaded onto 8% acrylamide gels that contained 2 mg/ml FITC-gelatin (custom made). After SDS–PAGE, the gels were washed twice for 20 min in 2.3% Triton X-100 and incubated for 10 days in zymography buffer (50 mM Tris [pH 7.5], 10 mM CaCl2, 1 mM ZnCl2, and 1% Triton X-100) at 37°C with gentle rocking. The gels were visualized under ultraviolet light. The intensity of white bands against the dark background was quantified using ImageJ software. MMP-9 activity was normalized to MMP-2 activity.

Locomotor hyperactivity

The experiments were performed on 2- to 3-month-old C57BL/6J Mmp-9 heterozygous mice and their wild-type siblings. Strain colony was maintained in the animal house of the Nencki Institute. Mice were maintained individually in ventilated cages with dimensions of 38 cm (length) × 23 cm (width) × 20 cm (height) with continuous access to water and food. The animals were provided with nesting material. The following conditions were provided for the mice: temperature of 21–23°C, humidity 50–60%, daily cycle 12/12 h (light phase from 7 to 19). One animal was excluded because of partially missing data. Seven Mmp-9 heterozygous mice (four females and three males) and eight wild-type mice (four females and four males) were subjected to the experiment.

Locomotor hyperactivity was induced by the noncompetitive NMDA receptor antagonist MK-801 (Sigma-Aldrich) as described (van den Buuse, 2010), with modifications. Mice were habituated to handling by the experimenter and the experimental room. The mice were then individually transported to the experimental room (with blinding to the genotype), placed in an open-field apparatus (40 cm × 40 cm), and allowed to freely explore the apparatus for 30 min. The mice then received an intraperitoneal injection of physiological saline and were returned to the open field for 1 h. Finally, the animals received an intraperitoneal injection of 0.25 mg/kg MK-801 and were allowed to explore the apparatus for 1 h. Behavior was monitored by a video camera that was placed above the center of the apparatus. The data were analyzed using EthoVision XT (Noldus). The distance traveled was analyzed starting 10 min after saline or drug injection.

All of the procedures were performed in accordance with the Animal Protection Act of Poland (Directive 2010/63/EU) and were approved by the 1st local ethics committee (permission no. 257/2012).
Statistical analysis

Sample sizes were designed to give statistical power. The case-control analysis and tests for deviation from Hardy–Weinberg Equilibrium (HWE) were performed using PLINK 1.07 software. The statistical analyses of phenotype-genotype associations in the human samples were performed using SPSS 17.0 software. For the analysis of the chronic delusion composite score, the Spearman rank correlation coefficient was calculated to assess the strength of association between two nonparametric variables. Cronbach’s α was calculated as a measure of internal consistency. In the present study, carriers of the MMP-9 rs20544-C allele (risk allele; CC/CT) were compared with TT carriers. Genotype differences with regard to the clinical measures were tested nonparametrically using the Mann–Whitney U-test (continuous variables).

Two-tailed Student’s t-test was used to analyze filter binding and data from the RNA gel-shift experiments. For the morphological analysis of dendritic spines, two-way analysis of variance (ANOVA) with post hoc analysis by Tukey’s multiple comparisons was used. Spine density was measured using two-way repeated-measures ANOVA with post hoc analysis by Tukey’s multiple comparisons. The Mann–Whitney U-test was used for the DQ-gelatin assay. For the behavioral experiment, two different groups were analyzed: wild-type and heterozygous after injection of saline & MK-801 by the behavioral experiment, two different groups were analyzed:

The statistical analyses were performed using GraphPad Prism 6 & STATISTICA 8 software. The data are expressed as mean ± standard error of the mean (SEM) except for the Fig EV3, on which mean ± standard deviation (SD) is shown. Values of P < 0.05 were considered statistically significant. The exact P-values from all experiments described in the manuscript are reported in the Table EV1.

Expanded View for this article is available online.

Acknowledgements

The authors would like to thank Michael Arends for carefully editing the manuscript. This work was supported by The Foundation for Polish Science (FNP) TEAM grant, the EXTRABRAIN 7th Framework Marie Curie European Union Initial Training Network grant and auxiliary support from the Polish Ministry of Science and Higher Education (UMOWA Nr 2948-7.PR-2013-2). GRAS was supported by the Max Planck Society, the Max Planck Förderstiftung, the DFG (CNMPB), EXTRABRAIN EU-FP7, the Niedersachsen-Research Network on Neuroinfektology (N-RENNT), and EU-AIMS.

Author contributions

Conceived the study: HE, MD,LK, and RWA Designed, performed, and analyzed the experiments: KL, KJP, KP-W, MM, MB, and BV Contributed unpublished reagent [purified FMRP]: KB Wrote the manuscript: KL, MD, HE, and LK.

Conflict of interest

The authors declare that they have no conflict of interest.

References

Ali FT, Abd El-Azeem EM, Hamed MA, Ali MAM, Abd Al-Kader NM, Hassan EA (2017) Redox dysregulation, immuno-inflammatory alterations and genetic variants of BDNF and MMP-9 in schizophrenia: pathophysiological and phenotypic implications. Schizophr Res doi:10.1016/j.schres.2017.01.016

American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders, 4th edn. Washington, DC: American Psychiatric Press

Areliano JI, Benavides-Piccione R, Defelipe J, Yuste R (2007) Ultrastructure of dendritic spines: correlation between synaptic and spine morphologies. Front Neurosci 1: 131 – 143

Bardin C, Leroy JL (2008) The formation pathway of tetramolecular G-quadruplexes. Nucleic Acids Res 36: 477 – 488

Begemann M, Grube S, Papilo S, Malzahn D, Krampe H, Ribbe K, Friedrichs H, Radyushkin KA, El-Kordi A, Benseler F et al (2010) Modification of cognitive performance in schizophrenia by complex 2 gene polymorphisms. Arch Gen Psychiatry 67: 879 – 888

Biesada M, Pachulski-Wiezorek A, Adamiak RW, Purzycka KJ (2016) RNAComposer and RNA 3D structure prediction for nanotechnology. Methods 103: 120 – 127

Bilousova TV, Dansie L, Ngo M, Aye J, Charles JR, Ethell DW, Ethell IM (2009) Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model. J Med Genet 46: 94 – 102

Bryant CD, Yazdani N (2016) RNA-binding proteins, neural development and the addictions. Genes Brain Behav 15: 169 – 186

van den Buuse M (2010) Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects. Schizophr Bull 36: 246 – 270

Chang S-H, Chiang S-Y, Chiu C-C, Tsai C-C, Tsai H-H, Huang C-Y, Hsu T-C, Tzang B-S (2011) Expression of anti-cardiolipin antibodies and inflammatory associated factors in patients with schizophrenia. Psychiatry Res 187: 341 – 346

Chopra K, Baveja A, Kuhad A (2015) MMPs: a novel drug target for schizophrenia. Expert Opin Ther Targets 19: 77 – 85

Comery TA, Harris JB, Willems PJ, Oostra BA, Irwin SA, Weiler IJ, Greenough WT (1997) Abnormal dendritic spines in fragile X knockout mice: maturation and pruning deficits. Proc Natl Acad Sci USA 94: 5401 – 5404

Darnell JC, Jensen KB, Jin P, Brown V, Warren ST, Darnell RB (2001) Fragile X mental retardation protein targets G quartet mRNAs important for neuronal function. Cell 107: 489 – 499

Darnell JC, Van Driessche SJ, Zhang C, Hung KYS, Mele A, Fraser CE, Stone EF, Chen C, Fak JJ, Chi SW et al (2011) FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell 146: 247 – 261

Deigan KE, Li TW, Mathews DH, Weeks KM (2009) Accurate SHAPE-directed RNA structure determination. Proc Natl Acad Sci USA 106: 97 – 102

Domenici E, Willé DR, Tozzi F, Prokopenko I, Miller S, McKeown A, Brittain C, Rujescu D, Giegling I, Turck CW et al (2010) Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. PLoS One 5: e9166

Dziembowska M, Milek J, Janusz A, Rejkmal E, Romanowska E, Gorkiewicz T, Tiron A, Bramham CR, Kaczmarek L (2012) Activity-dependent local translation of matrix metalloproteinase-9. J Neurosci 32: 14538 – 14547

Dziembowska M, Pretto DI, Janusz A, Kaczmarek L, Leigh MJ, Gabriel N, Durbin-Johnson B, Hagerman RJ, Tassone F (2013) High MMP-9 activity levels in fragile X syndrome are lowered by minocycline. Am J Med Genet Part A 161: 1897 – 1903

Fatemi SH, Kneeland RE, Liesch SB, Folsom TD (2010) Fragile X mental retardation protein levels are decreased in major psychiatric disorders. Schizophr Res 124: 246 – 247

Gkogkas CG, Khitousky A, Cao R, Jafarnejad SM, Prager-Khoutorsky M, Giannakas N, Kaminari A, Fragkouli A, Nader K, Price TJ et al (2014)
Pharmacogenetic inhibition of eIF4E-dependent Mmp9 mRNA translation reverses fragile X syndrome-like phenotypes. Cell Rep 9: 1742–1755
Glauser JR, Lewis DA (2013) Dendritic spine pathology in schizophrenia. Neuroscience 251: 90–107
Gunduz-Bruce H (2009) The acute effects of NMDA antagonism: From the rodent to the human brain. Brain Res Rev 60: 279–286
Gurling HM, Kalsi G, Brynjolfsson J, Sigmundsson T, Sherrington R, Mankoo BS, Read T, Murphy P, Blavie E, McQuillin A et al (2001) Genomewide genetic linkage analysis confirms the presence of susceptibility loci for schizophrenia, on chromosomes 1q32.2, 9q33.3, and 8p21-22 and provides support for linkage to schizophrenia, on chromosomes 1q23.3-24 and 20q12.1-11.23. Am J Hum Genet 68: 661–673
Guy W (1976) Clinical global impression (CGI). In ECDEU assessment manual for psychopharmacology, revised, Guy W (ed.), pp 218–222. Rockville, MD: US Dept of Health, Education, & Welfare
Hammer C, Stepniak B, Schneider A, Papiol S, Tantra M, Begemann M, Sirén A-L, Pardo LA, Sperling S, Mohd Jaffry S et al (2014) Neuropsychiatric disease relevance of circulating anti-NMDA receptor autoantibodies depends on blood–brain barrier integrity. Mol Psychiatry 19: 1143–1149
Han H, He X, Tang J, Liu W, Liu K, Zhang J, Wang X, Xu Y, Chen X (2013) The C(–1562)T polymorphism of matrix metalloproteinase-9 gene is associated with schizophrenia in China. Psychiatry Res 190: 163–164
Harris KM, Stevens JK (1989) Dendritic spines of CA1 pyramidal cells in the rat hippocampus: serial electron microscopy with reference to their biophysical characteristics. J Neurosci 9: 2982–2997
Hou L, Antion MD, Hu D, Spencer CM, Klann E (2011) Decreased fragile X mental retardation protein regulates dendritic spine structure by direct targeting of AMPA receptor subunits. Mol Psychiatry 16: 1149–1161
Huang Q, Purzycka KJ, Kaczmarek L (2015) Ty1 retrovirus-like element Gag contains overlapping restriction factor and nucleic acid chaperone functions. Nucleic Acids Res 43: 7414–7431
Hou L, Antion MD, Hu D, Spencer CM, Paylor R, Klann E (2006) Dynamic translational and proteasomal regulation of fragile X mental retardation protein controls mGluR-dependent long-term depression. Neuron 51: 441–454
Huang Q, Purzycka KJ, Lepeta K, Kaczmarek L, Dziembowska M (2011) The positive and negative syndrome scale for psychopharmacology, revised. Ann Hum Genet 59: 719–730
Huygens KM, Stovel RC, Zaleski J, Pombo-Villar J, Zeng X, Roufogalis BD, Crewther C, Baker D et al (2012) Matrix metalloproteinase-9 mRNA is associated with severity of schizophrenia, and provides support for linkage to schizophrenia, on chromosomes 1q23.3-24 and 20q12.1-11.23. Am J Hum Genet 68: 661–673
Huang Q, Purzycka KJ, Kaczmarek L (2015) Matrix metalloproteinase-9 as a novel player in synaptic plasticity and schizophrenia. Schizophr Bull 41: 1003–1009
Lee JY, Yoon J, Kim HW, Kim DS (2008) Structural diversity and extreme stability of unimolecular Oxytricha nova telomeric G-quadruplex. Biochemistry 47: 3389–3396
Lepeta K, Kaczmarek L (2015) Matrix metalloproteinase-9 is associated with schizophrenia in China. Schizophr Bull 41: 1003–1009
Levy AD, Omar MH, Kolesse AJ (2014) Extracellular matrix control of dendritic spine and synapse structure and plasticity in adulthood. Front Neuroanat 8: 116
Lin Y-C, Kolesse AJ (2010) Mechanisms of synapse and dendrite maintenance and their disruption in psychiatric and neurodegenerative disorders. Annu Rev Neurosci 33: 349–378
Martin KC, Ehrhussi A (2009) mRNA localization: gene expression in the spatial dimension. Cell 136: 719–730
Muddashetty RS, Kelic S, Gross C, Xu M, Bassell GJ (2007) Dysregulated metabotropic glutamate receptor-dependent translation of AMPA receptor and Postsynaptic Density-95 mRNAs at synapses in a mouse model of fragile X syndrome. J Neurosci 27: 5338–5348
Network and Pathway Analysis Subgroup of Psychiatric Genomics Consortium TN and PAS of the PG (2015) Psychiatric genome-wide association study analyses implicate neuronal, immune and histone pathways. Nat Neurosci 18: 199–209
Niedringhaus M, Chen X, Dzakpasu R, Conant K (2012) MMPs and soluble ICAM-5 increase neuronal excitability within in vitro networks of hippocampal neurons. PLoS One 7: e42631
Nishiya Y, Pachulska-Wieczorek K, Blaszczzyk L, Saha A, Gumna J, Garfinkel DJ, Purzycka KJ (2015) Ty1 retrovirus-like element Gag contains overlapping restriction factor and nucleic acid chaperone functions. Nucleic Acids Res 43: 7414–7431
Otmakhov N, Khinik L, Otmakhova N, Carpenter S, Riahi S, Asrican B, Lisman J (2004) Forskolin-induced LTP in the CA1 hippocampal region is NMDA receptor dependent. J Neurophysiol 91: 1955–1962
Pachulska-Wieczorek K, Purzycka KJ, Adamiak RW (2006) New, extended hairpin form of the TAR-2 RNA domain points to the structural polymorphism at the S’ end of the HIV-2 leader RNA. Nucleic Acids Res 34: 2984–2997
Penzes P, Cahill ME, Jones KA, VanLeeuwen J-E, Woolfrey KM (2011) Dendritic spine pathology in neuropsychiatric disorders. Nat Neurosci 14: 285–293
Popenda M, Szachniuk M, Antczak M, Purzycka KJ, Lukasiak P, Bartol N, Blazewicz J, Adamiak RW (2012) Automated 3D structure composition for large RNAs. Nucleic Acids Res 40: e112
Purzycka KJ, Pachulska-Wieczorek K, Adamiak RW (2011) The in vitro loose dimer structure and rearrangements of the HIV-2 leader RNA. Nucleic Acids Res 39: 7234–7248
Purzycka KJ, Legiewicz M, Matsuda E, Eizenstat LD, Lusvarghi S, Saha A, Le Grice SF, Garfinkel DJ (2013) Exploring Ty1 retrotransposon RNA structure within virus particles. Nucleic Acids Res 41: 463–443
Radyushkin K, El-Kordi A, Boretius S, Castaneda S, Ronnenberg A, Reim K, Niedringhaus M, Chen X, Dzakpasu R, Conant K (2012) MMPs and soluble ICAM-5 increase neuronal excitability within in vitro networks of hippocampal neurons. PLoS One 7: e42631
Ribe K,Acknowledgment of funding support. This work was supported by the Swedish Research Council (K2013-51X-21235-01-4), the Karolinska Institutet and the Stockholm County Council, Sweden, the Swedish Children’s Cancer Society, and the Swedish Society of Medicine. We thank Anna Borelius and Sofia Leiva for technical assistance and Erik Lundstrom for excellent photography. The model was kindly provided by Patricia H. Green. The authors declare that there is no conflict of interest. 

© 2017 The Authors

EMBO Molecular Medicine Vol 9 | No 8 | 2017 1115
comorbid alcoholism in schizophrenia by interaction of common genetic variants in the corticotropin-releasing factor system. *Arch Gen Psychiatry* 68: 1247–1256

Rudelli RD, Brown WT, Wnisiewski K, Jenkins EC, Laure-Kamionowska M, Connell FWH (1985) Adult fragile X syndrome. Clinico-neuropathologic findings. *Acta Neuropathol* 67: 289–295

Ruszczyński B, Szepesi Z, Wilczynski GM, Bijata M, Kalita K, Kaczmarek L, Wlodarczyk J, Yuste R, Denk W, Segal M et al (2012) Sampling issues in quantitative analysis of dendritic spines morphology. *BMC Bioinformatics* 13: 213

Rybakowski JK, Skibinska M, Kapelski P, Kaczmarek L, Hauser J (2009) Functional polymorphism of the matrix metalloproteinase-9 (MMP-9) gene in schizophrenia. *Schizophr Res* 109: 90–93

Schizophrenia Working Group of the Psychiatric Genomics Consortium (2014) Biological insights from 108 schizophrenia-associated genetic loci. *Nature* 511: 421–427

Sidhu H, Dansie LE, Hickmott PW, Ethell DW, Ethell IM (2014) Genetic removal of matrix metalloproteinase 9 rescues the symptoms of fragile X syndrome in a mouse model. *J Neurosci* 34: 9867–9879

Stepniak B, Papiol S, Hammer C, Ramin A, Everts S, Kästner A, Poggi G, Mitjans M, Begemann M, Ehrenreich H (2014) Accumulated environmental risk determining age at schizophrenia onset: a deep phenotyping-based study. *Lancet Psychiatry* 1: 444–453

Stepniak B, Kastner A, Poggi G, Mitjans M, Begemann M, Hartmann A, van der Auwera S, van der Auwera M, Krueger-Burg D, Matuszko G et al (2015) Accumulated common variants in the broader fragile X gene family modulate autistic phenotypes. *EMBO Mol Med* 7: 1565–1579

Szepesi Z, Bijata M, Ruszczycki B, Kaczmarek L, Wlodarczyk J (2013) Matrix metalloproteinases regulate the formation of dendritic spine head protrusions during chemically induced long-term potentiation. *PLoS One* 8: e63314

Szepesi Z, Hosy E, Ruszczycki B, Bijata M, Pyskaty M, Bikbaev A, Heine M, Choquet D, Kaczmarek L, Wlodarczyk J et al (2014) Synaptically released matrix metalloproteinase activity in control of structural plasticity and the cell surface distribution of GluA1-AMPA receptors. *PLoS One* 9: e98274

Szklarczyk A, Lapinska J, Rybski M, McKay RDG, Kaczmarek L (2002) Matrix metalloproteinase-9 undergoes expression and activation during dendritic remodeling in adult hippocampus. *J Neurosci* 22: 920–930

Thévenaz P, Ruttimann UE, Unser M (1998) A pyramid approach to subpixel registration based on intensity. *IEEE Trans Image Process* 7: 27–41

Vafadari B, Salamian A, Kaczmarek L (2016) MMP-9 in translation: from molecule to brain physiology, pathology, and therapy. *J Neurochem* 139: 91–114

Vasa SM, Guex N, Wilkinson KA, Weeks CM, Giddings MC (2008) ShapeFinder: a software system for high-throughput quantitative analysis of nuclear acid reactivity information resolved by capillary electrophoresis. *RNA* 14: 1979–1990

Wang X, Bzdagdi O, Nikitczuk JS, Zhai ZW, Zhou Q, Huntley GW (2008) Extracellular proteolysis by matrix metalloproteinase-9 drives dendritic spine enlargement and long-term potentiation coordinately. *Proc Natl Acad USA* 105: 19520–19525

Wieczorek P, Wieczorek KP, Błaszczyk L, Biesiada M, Adamik RW (2016) The matrix domain contributes to the nucleic acid chaperone activity of HIV – 2 Gag. *Retinovirology* 13: 18

Wilczynski GM, Konopacki FA, Wilczek E, Lasiecka Z, Gorlewicz A, Michaluk P, Wawrzy niak M, Malinowska M, Okulski P, Kolodziej LR et al (2008) Important role of matrix metalloproteinase 9 in epileptogenesis. *J Cell Biol* 180: 1021–1035

Yamamoto H, Hashimoto R, Ishima T, Kishi F, Yasuda Y, Ohki K, Fujimoto M, Umeda-Yano S, Ito A, Hashimoto K et al (2013) Plasma levels of mature brain-derived neurotrophic factor (BDNF) and matrix metalloproteinase-9 (MMP-9) in treatment-resistant schizophrenia treated with clozapine. *Neurosci Lett* 556: 37–41

Yuste R, Bonhoeffer T (2004) Genesis of dendritic spines: insights from ultrastructural and imaging studies. *Nat Rev Neurosci* 5: 24–34

Zalfa F, Giorgi M, Primerano B, Moro A, Di Penta A, Reis S, Oostra B, Bagni C (2003) The fragile X syndrome protein FMRP associates with BC1 RNA and regulates the translation of specific mRNAs at synapses. *Cell* 112: 317–327

License: This is an open access article under the terms of the Creative Commons Attribution 4.0 License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.